nobody cares for eps numbers as the stock is trading at a pe of 100 anyway - user and transaction metrics are the drivers of future revenue and earnings growth and they came in pretty weak
Q3 and full year outlook are pretty much in line with estimates - they even raised the low end of their FY revenue guidance by $1 mln. But the transaction volume growth and the new user decrease look troublesome
who cares about coffee prices here - the company does not profit in any way. If prices go up their customers refuse to buy until either JVA sells at a discount or market prices come back as evidenced last quarter. If prices go down the companies top and bottom line gets even more pressured. Long term investors can't win anything here as evidenced by the 10-year-chart. Except for two undeserved short term time frames where the shares were picked up by the momentum crowd the share price is pretty much the same as it was 10 years ago. Sell.
because they were wrong so far - this was a poor piece of research at that time with MW just trying to capitalize on their previously earned merits. Coupled with the even weaker SPRD piece they lost plenty of reputation at that time
the exchange listing is just a vehicle for the Gordon brothers to dump their freshly printed new share awards into the market from time to time. Given that this is a family owned business their would be zero need otherwise for an exchange listing.
just why ? the company has never delivered up to anything for a longer term time frame. They never bought back a single share to my knowledge (they actually print tons of new ones every year to serve the Gordon brothers) and there's no reason to believe this will ever change. The CEO is already over 50 so why should he bother for outside shareholders ? He will print shares another 10 years and then retire and the company being closed. Or perhaps led by his younger brother for some more years and then closed.
The metric means nothing - after all they are an intermediary on the coffee market which means high revenues and low margins. To make things worse dependent on coffee prices revenues (not to speak of earnings) have been highly volatile in the past. Better look at book value discounted for several worthless items on the balance sheet.
the beat was almost solely caused by the company being behind its hiring plan. And reaffirming guidance after revenues for the quarter came in above plan is actually a guide down as evidenced by management's comments on the call.
as evidenced last quarter they are easily able to ride out short term price fluctuations, JVA was forced to sell coffee at a discount to market prices to get at least SOMETHING sold. Now the price has come back nicely and they can restock much cheaper. Anyway JVA has consistently shown that they are not able to benefit from coffee price fluctuations due to their weak position in the market.
you might not like it but JVA won't be able to capitalize on ANY movement in the coffee price - they had some cheap inventory when prices went up but guess what happened ? Their customers simply refused to buy and they actually had to offer their stockpile at DISCOUNTED prices to get at least some inventory sold. The cheap inventory will soon be sold out and they will have to buy at market prices again. The company has consistently shown that it is not in a position to deliver sustained profits or even successfully ride the coffee market waves. It is just a shame.
bookings more than 50% below expectations, $300 mln wasted for a nursing case, physicians signing behind expectations, Accenture cooperation below plan - almost everything below expectations
it is pretty hard to figure out why the shares are trading above $50
bookings once again below expectations which will take a toll on future revenues and earnings - valuation looks still extreme here given that things won't improve short to medium term. Sell.
actually the eps does mean little for a growth stock like ATHN - it is all about revenue and ecosystem growth and these metrics have been slowing last quarter. Revenues came in above analyst estimates though. Management will have to defend itself against analyst questions on the call especially with regards to the slowdown in physicians growth.
- epocrates revenues a shame
- revenue growth rate down
- physician growth rate down
clearly there's not much to celebrate here given the stock's valuation. Waiting for cc.
I am short a few thousand shares here as the daily trading volume just doesn't support a bigger involvement. I would expect next quarter's earnings to again heavily underperform investor expectations (perhaps even red ink) and even worse times going forward as the company will be out of cheap inventory by that time. It's hard to remember another company which is less worth investing in.
If anyone would make his decisions based on my Yahoo message board postings I certainly would sell short BEFORE making a negative posting.